Company continues to innovate across its portfolio to address critical unmet needs in neurovascular intervention

SAN MATEO, Calif.–(BUSINESS WIRE)–Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the company’s 80th global issued patent for its Monopoint® Operating Platform. The Monopoint® Operating Platform is the only neurointervention platform designed to streamline delivery of large and super-bore catheters for aspiration at the most common stroke targets. The single-platform system is designed for efficient and effective neurovascular intervention with a design that eliminates length challenges and provides a single point of control for enhanced single-operator capability.

“Route 92 Medical is poised to disrupt the neuro-interventional market with products that are designed to treat ischemic strokes by enhancing delivery in challenging anatomy using our unique single-point-of-control approach,” said Tony Chou, M.D., founder, and chief executive officer at Route 92 Medical. “Our intellectual property strength, combined with our world-class team, give us a strong position from which we can make a positive difference in the lives of stroke patients and their families.”

The company’s newest patent, U.S. Patent No. 11,576,691, relates to the company’s innovative Tenzing® delivery catheter for advancing catheter systems within the neurovasculature. The Tenzing® catheter is part of the Monopoint® platform, which is designed to enable a single operator to perform even the most complex procedures to treat large vessel occlusions that cause acute ischemic stroke.

“The past twenty years have seen extensive research on patient selection for stroke intervention with limited device innovation,” said John Miller, chief technology officer at Route 92 Medical. “We are focused on simplifying neurovascular procedures so physicians can reduce procedure times and improve clinical outcomes.”

Route 92 Medical has a global intellectual property position with strong protection for its inventions in key markets including the U.S., Europe, and China. The company patent portfolio is growing rapidly with 46 patents issued in 2022 including patents with claims across the company’s Monopoint® portfolio, including its Tenzing® and HiPoint™ catheter devices.

About Route 92 Medical, Inc.

Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering and innovative product design. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn.

Contacts:

For media:
Gwen Gordon
Gwen Gordon PR
[email protected]